Germany Begins its First AIDS Vaccine Trial, Partnering with IAVI

17-Feb-2004

Berlin - German scientists, working as part of an international partnership, are beginning the country's first human trial of a vaccine candidate designed to prevent AIDS. A preventive vaccine is widely considered the best hope to stop the epidemic's continuing spread.

The trial will be conducted at two sites: Universitaetsklinikum Bonn and Universitaetsklinikum Eppendorf in Hamburg. The universities are partnering with the not-for-profit International AIDS Vaccine Initiative (IAVI), the biotechnology company Targeted Genetics Corp. (Nasdaq: TGEN) and Columbus Children's Research Institute (CCRI).

Government regulatory approval to begin the trial has been granted by the Kommittee fuer Somatische Gentherapie (KSG).

Reminding people about vaccinations can increase rates of immunization

Read news

Dr. Jan van Lunzen, MD, serves as Principal Investigator of the trial. Dr. van Lunzen said: "Preventive vaccines have ended smallpox, nearly eradicated polio and controlled dozens of other deadly diseases. With this new trial in Germany, we bring the world a step closer to a vaccine that will end AIDS."

The vaccine candidate being tested in the trial is named tgAAC09. It was designed by Targeted Genetics and CCRI. tgAAC09 attempts to elicit immune system responses to prevent people from becoming infected with HIV and developing AIDS.

IAVI provides full financial support for the research and development of tgAAC09. Dr. Seth Berkley, MD, President and CEO of IAVI, said: "We are pleased that Germany's top scientists are joining the global effort to develop a preventive AIDS vaccine. Their commitment is crucial as we speed progress toward a vaccine."

Deutsche AIDS Stiftung (DAS), Germany's national AIDS advocacy group, hailed the start of the trial: "We will win against AIDS only by fighting on multiple fronts. As Germany works to blunt AIDS with existing tools, we must also search for new tools, chief among them a preventive vaccine," said Ulrich Heide, Chief Executive Officer of DAS.

The trial is also being conducted in Belgium. The trial will enroll up to 50 volunteers, men and women, in Germany and Belgium combined. It will test the safety of tgAAC09 and if it elicits immune responses. If so, tgAAC09 may advance to more and larger trials.

Each day, 14,000 people become infected with HIV, 95% in developing countries. Worldwide, IAVI estimates, roughly 25 preventive vaccine candidates are in human trials on six continents. Five of these advanced from the concept stage to trials with IAVI support.

https://www.bionity.com/en/news/35405/germany-begins-its-first-aids-vaccine-trial-partnering-with-iavi.html